Segment Information

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Segment Information

(12)        Segment Information

The Company has four reportable segments which include: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, and Fluorine Products. The Company had five reportable segments in 2021 which also included Radiological Services. The Radiological Services business segment included field services, gemstone processing, and source disposal. As the Company is no longer engaged in field services and gemstone processing, which made up the substantial portion of activities of this segment, separate reporting of this segment has been discontinued. The Company continues to engage in source disposal activities and has begun reporting these activities under the Nuclear Medicine Standards segment starting January 1, 2022. Additionally, the Company reclassified its reporting for 2021 to include all activities for the Radiological Services business segment under the Nuclear Medicine Standards segment.

Information regarding the operations and assets of these reportable business segments is contained in the following table:

	Three months ended September 30,				Nine months ended September 30,
Sale of Product	2022		2021		2022		2021
Radiochemical Products	$	1,298,667	$	1,210,615	$	4,304,629	$	3,100,001
Cobalt Products		424,731		408,808		695,783		1,104,176
Nuclear Medicine Standards		1,065,875		990,328		3,031,110		3,135,970
Fluorine Products		—		7,763		—		29,775
Total Segments		2,789,273		2,617,514		8,031,522		7,369,922
Corporate revenue		—		—		—		—
Total Consolidated	$	2,789,273	$	2,617,514	$	8,031,522	$	7,369,922

	Three months ended September 30,				Nine months ended September 30,
Depreciation and Amortization	2022		2021		2022		2021
Radiochemical Products	$	7,102	$	77,740	$	56,447	$	235,717
Cobalt Products		12,087		12,399		36,368		38,437
Nuclear Medicine Standards		28,710		27,043		85,943		61,785
Fluorine Products		26,095		28,649		78,285		85,902
Total Segments		73,994		145,831		257,043		421,841
Corporate depreciation and amortization		10,502		7,636		31,004		18,876
Total Consolidated	$	84,496	$	153,468	$	288,047	$	440,718

	Three months ended September 30,						Nine months ended September 30,
Segment Income (Loss)	2022			2021			2022			2021
Radiochemical Products	$	454,223		$	370,586		$	3,430,516		$	779,468
Cobalt Products		(134,044	)		166,808			(189,451	)		345,292
Nuclear Medicine Standards		65,171			133,185			76,743			506,590
Fluorine Products		(37,204	)		(26,585	)		(111,377	)		(91,725	)
Total Segments		348,146			643,994			3,206,431			1,539,623
Corporate loss		(916,815	)		(780,863	)		(2,792,103	)		(2,459,031	)
Net (Loss) Income	$	(568,669	)	$	(136,869	)	$	414,328		$	(919,408	)

	Three months ended September 30,				Nine months ended September 30,
Expenditures for Segment Assets	2022		2021		2022		2021
Radiochemical Products	$	—	$	—	$	—	$	3,103
Cobalt Products		—		—		—		16,592
Nuclear Medicine Standards		4,150		5,064		55,250		172,975
Fluorine Products		—		—		4,100		4,060
Total Segments		4,150		5,064		59,350		196,730
Corporate purchases		8,925		—		8,925		—
Total Consolidated	$	13,075	$	5,064	$	68,275	$	196,730

	September 30,		December 31,
Segment Assets	2022		2021
Radiochemical Products	$	890,369	$	2,890,590
Cobalt Products		697,752		597,420
Nuclear Medicine Standards		1,476,708		2,259,759
Fluorine Products		5,176,296		5,258,823
Total Segments		8,241,125		11,006,592
Corporate assets		8,624,628		5,320,550
Total Consolidated	$	16,865,753	$	16,327,142